Q2 2025 Certara Inc Earnings Call
Good day and thank you for standing by. Welcome to the Sitara second quarter 2025 earnings conference call.
At this time, all participants are in a listen-only mode.
After the speaker's presentation, there will be a question and answer session to ask a question during the session. You will need to press star 1, 1 on your telephone. You will then hear an automated message. Advising your hand is raised to withdraw your question. Please press star 1 1 again, please be advised. That today's conference is being recorded.
I would now like to hand the conference over to your first Speaker today. David declar investor relations, please go ahead.
Good afternoon, everyone. Thank you all for participating in today's conference. Call on the call from Sitara, we have William Furey chief executive officer and John Gallagher Chief Financial Officer earlier today. Sir, Tara released Financial results for the quarter ended, June 30th 2025, a copy of the press release is available on the company's website.
Before we begin, I would like to remind you, that management will make statements during this call that include forward-looking statements and actual results May differ, materially from those expressed or implied in the forward-looking statements, please refer to slide 2 in the accompanying materials for additional information which you can find on the company's investor relations website in their remarks or responses. To questions management May mention some non-gaap Financial measures. Reconciliations of these non-gaap Financial measures to the most directly comparable. Gaap measures are available in the most recent earnings press release available on the company's website.
Please refer to the reconciliation tables in the company materials for additional information.
The conference call contains time-sensitive information, and is accurate only as of the live broadcast today, August 6th 2025. So Target is claims any obligation, except as required by law to update, or revise, any Financial projections or forward-looking statements, whether because it's new information, future events or otherwise. And with that, I will turn the call over to William.
Thank you, David and good afternoon, everyone. Thank you for joining sart's. Second quarter earnings call.
John and I will begin with prepared remarks and then we will take your questions.
So Tara's second quarter performance, reflected continued strength, that crossed the organization. As we achieve results that were consistent with our full year, outlook in both software and services.
Second quarter revenue of 104.6 million represented 12%, year-over-year growth, my second quarter, bookings of 112 million reflected 13% year-over-year growth.
Relative to internal expectations. We are pleased with the state of our financial performance and sales funnel as we head into the second half of the year.
Across the portfolio.
We continue to see strength in high growth areas such as qst services and our Sim sip software.
We have a high degree of visibility into second, half software Performance Based on the mix of renewals in our pipeline.
Which gives us additional confidence in our full year growth expectations.
In services, our commercial team continues to execute in line or ahead of our expectations. Delivering 15% bookings. Growth in 2q and 10% bookings growth on a trailing 12-month basis.
Which supports the revenue Outlook through the rest of the year?
As a result of our strong, year-to-date execution, we are reiterating our full year guidance.
Across a variety of customer groups are conversations. Continue to reflect a mixed spending environment in our various and markets
Large Pharma companies remain cautious driven by a rapidly changing geopolitical and macroeconomic environment.
Decision-making timeline. For our customers have been affected by proposed. Pharmaceutical tariffs.
And the potential introduction of a most favored nation pricing algorithm.
Among smaller customers, the biotech funding environment has slightly improved but it remains below trend on a historical basis.
Despite these headwinds, we have been encouraged by persistent interests, from customers seeking to expand their use of Bio simulation technology incorporating additional Sitara products and services into their development workflows.
Throughout the second quarter, our team did an excellent job of remaining in front of key stakeholders and facilitating discussions about how we can further expand existing relationships.
now, turning to our second quarter commercial performance,
In software, we saw strong bookings performance across tiers 2 and 3, offset by timing-related softness into Tier 1, which remains in line with plan on a year-to-date basis.
7 million grew 22% on a reported basis of 9%, organically led by strong growth from Sims.
in addition to 5.1 million of contribution from Kim Axon,
In Services, we saw bookings growth across all 3 of our customer tears. Led by strength and Tier 1 across both bio simulation and Regulatory services.
Strength, and bio simulation Services. Bookings was driven by qst and Sim sip services.
While total regulatory. Bookings. Also grew nicely during the quarter.
Services. Revenue of 57.9 million grew 5%, on a reported basis.
So Tara Sim reached a significant regulatory Milestone earlier this week. We're happy to share that Sitara is the first and only company to receive European medicines agency EMA qualification for a PVP K modeling platform.
And Sim sip is the only software to hold this designation.
The recognition follows a rigorous multi-year collaborative engagement between Sitara scientists technologists and the EMA.
The qualification is a significant milestone for Bio, simulation, demonstrating the value. That Regulators place on evidence generated through modeling and simulation approaches. And it will continue to encourage the usage of cimsit by companies globally.
So Tara is continuing to increase investment in R&D to create our next Generation, AI enabled midv platform.
This investment started in 2022 before the breakthroughs in GPT AI were announced when Sitara acquired Vasa.
Vasa brought to satara the foundational distributed data Fab fabric technology, which has become the underpinning of our ability to integrate AI with our modeling technology and data sets.
Since then, we have utilized this technology in a number of new AI features in our products. And also some new important AI products, like co-author,
Last week, I was pleased to announce the promotion of Dr. Christopher Bhutan, founder of Vyasa, as Certara's CTO.
Chris is leading the integration of satara key MDD modeling tools into our next Generation, AI MDD platform, which will be launching over the next year.
We believe that Sitara can solidify our leading position in the midv with this platform which will fuse both, Ai and bio simulation technology to enable our customers to reduce the risk and cost of drug development.
The next step in the creation of this platform will be the release this fall of satara IQ. An AI enabled qsp, software solution that includes an intuitive model building interface and several pre-validated, qsp models,
As you will recall, qsp, is 1 of the fastest growing markets within model. Informed drug development. And we have the largest group globally serving these customers
our services team will adopt sertar IQ as their preferred platform for executing qsp products, leveraging, Cutting Edge features and modeling capabilities.
With Sitara IQ customers will have 1 unified qsp platform to reference in collaboration with peers certara and regulators.
The product will be based in the cloud.
Allowing for high performance, simulation and Analysis work at faster speeds.
We believe this product launches a critical step in growing. The market for qsp solutions by democratizing access to modeling capabilities, across our customers which should ultimately lead to more qsp use in clinical development.
The product is currently in an Early Access phase with several customers, and we expect to announce a full commercial launch at some point in the fourth quarter.
while we are on the subject of qsp.
We received an update on our qsp collaboration with IGI, which was published in nature cancer last fall.
Our qsp team worked with IGI to optimize the first in human dose of ISB 2001.
Resulting in a clinical, starting dose, that was 50 to 100 fold over the conventional starting dose.
And that reduced the need for animal testing.
These predictions were validated by first in human trial results that were presented at aacr. This year, and ISB 2001 was granted a FasTrak designation for the treatment of relapsed refractory myeloma patients in May.
in the impact that qsp can have in accelerating trial, timelines, and accelerating the delivery of treatments to patients in need
In addition, excitement about new approach methodologies and particularly model. Informed drug development has grown in the wake of the fda's guidance to phase out animal testing for monoclonal antibodies.
While it's still too early to provide a precise estimate of the broader opportunity. We do view it as a multi-billion dollar addressable Market over the next 10 years.
We're excited to share that our qsp and broader Simpson. Businesses have begun to recognize bookings and revenue associated with a replacement of animal testing.
Roughly 50% of our new qsd projects. This year have been for monoclonal antibody Therapies.
Which is a testament to SARS competitive positioning as the leader in qsp and services, as well as the growing momentum of Nom use in clinical development processes.
Our acquisition of Applied biomass in late 2003 and the subsequent combination of our 2. Qs. P teams has proven timely and it's becoming an increasingly important component of our overall growth.
Now, shifting towards some other product related updates.
During the quarter, we released version 8.6 of our Phoenix pkpd platform following months of development and incorporating feedback, from Key stakeholders,
New enhancements included in the update were improved speed and efficiency of NCA setup data preparation. And the speed of nonlinear mixed effect algorithms for population, phico Kinetix.
As we have discussed in the past, this product has been made available through the Sitara Cloud offering faster performance with lower back-end, it costs for our customers.
Initial feedback from our users has been positive and we look forward to collaborating with them to drive further improvements to the Phoenix platform.
Another key Focus area for investment. Over the past, several quarters was our Pinnacle 21 product Suite, which is core to the data component of the software business.
Following the acquisition of for medics in late 2023, our team began to integrate Pinnacle 21 and for medic.
Data standardization capabilities.
Seeking to improve our customers, clinical data, workflows and timelines.
In early July, we were pleased to announce a new collaboration with MK expanding their use of Pinnacle 21st standardization capabilities.
this collaboration helped us build upon our long-standing relationship with MK, which is an example of the type of Engagement that Sitara is striving to build a cross, our customer base,
Our commercial team remains focused on identifying opportunities to form stronger Partnerships, with customers, both through the expansion of existing capabilities, to more seats and expansion of new products and services.
As we add to our portfolio, organically and inorganically, our land, and expand commercial strategy remains top of mind.
Now, before handing things over to John, I wanted to provide an update on the Strategic review of our regulatory business.
regulatory bookings have continued to grow nicely, through the quarter, and we continue to evaluate the business, given the profitability and cash flows, that it generates
Over the past several months, we have continued to make good progress in our review. However, this process has taken longer than we expected which we attribute in part to the unprecedented nature of geopolitical and macroeconomic uncertainty that has taken place since the beginning of the year.
With that said, we have maintained an active dialogue with several interested, external parties with discussions, progressing beyond the initial phases of diligence.
We hope to be able to provide a more substantive update before the end of 2025.
To close.
Pleased with our second quarter performance. And we are confident in our financial outlook for the remainder of the year.
Our guidance is supported by solid booking trends in services and high visibility into the second half, renewal dynamics, and software.
Customer interests in model, informed drug development continues to grow stronger. Each quarter supporting our growth strategy and validating the Investments. We are making in our business.
We look forward to continuing success and momentum during the second half of 2025.
With that, I will hand things over to John Gallagher to discuss our financial results in more detail.
Hello everyone. Total revenue for the 3 months. Ended June 30th, 2025 was 104.6 Million representing year-over-year growth of 12%. On a reported basis and 10% on a constant currency basis.
Total bookings. In the second quarter were 112 million which increased 13% from the prior year period on a reported basis.
Trailing 12-month bookings were 470.8 million increasing 15% on a reported basis.
Excluding to Maxon total company organic. Bookings growth was 8% compared with the second quarter last year.
Software Revenue was 46.7 million in the second quarter, which increased 22% over the prior year period on a reported basis and 20% on a constant currency basis.
Organic growth was 9% in the quarter driven by strong growth from SIM sip.
To Maxon contributed 5.1 million to our reported Revenue, which was in line with our expectations.
Routable and subscription Revenue accounted for 60% of second quarter software revenues or 64%. When excluding kmax on slightly down from 65% in the prior year, period.
Software, bookings, were 46.6 million in the second quarter, which increased 11% from the prior year. Period.
Second quarter, bookings included. 5.2 million of kamekona.
Trailing 12-month software bookings were $181.9 million, up 25% year-over-year.
Rate was 107.6 in the quarter consistent with our full year plan.
Looking at our software, bookings, performance by tier. We saw strong performance in tier 2 and 3 driven by continued adoption of our software. In Tier 1. We saw some timing related slowness, due to a renewals, which we expect to normalize in the second half of the year.
Now turning to Services Revenue which was 57.9 million in the second quarter up 5% versus the prior year period on a reported basis and 4% on a constant currency basis.
We saw strong performance from our qsp and Sim FIP Services businesses in the quarter, which was partially offset by softness and Regulatory services.
Technology-driven Services. Bookings. In the second quarter were 65.4 million, which increased 15% from prior year, period.
TTM Services. Bookings were 288.9 million up 10% as compared to the prior year.
During the quarter, we saw an improved demand for our bio simulation services with bookings growth across, all 3 of our customer tears. We were also encouraged by regulatory writing bookings. Which grew mid single digits for the second quarter of 2024.
Total cost of revenue for the second quarter of 2025 was 40.7 Million, an increase of 39.8 million.
in the second quarter of 2024, primarily due to higher software amortization, expense offset by lower stock-based compensation,
Total operating expenses for the second quarter of 2025 were 54.3 million a decrease from 62.5 million in the second quarter of 2024, primarily due to an 8.5 million, decrease in the change, in fair, value of a contingent consideration, which was offset by higher sales and marketing, expense and intangible asset amortization.
Adjusted, Evita for the second quarter of 2025 was 31.9 Million an increase from 26.3 million dollars. In the second quarter of 2024 adjusted, Evita margin in the quarter was 31%.
As Bill mentioned earlier, we are executing on our investment plans this year and have begun hiring additional software developers in the second quarter, which will continue through the second half of the year.
Total expenditure on R&D during 2 Q. Including capitalized, spend is growing year-on-year as a result of these Investments.
Wrapping up the income statement, net loss for the second quarter of 2025 was million dollars compared to a net loss of 12.6 million in the second quarter of 2024.
7.4 million to the second quarter of 2024.
Diluted loss per share for the second quarter of 2025 was 1 cent compared to a loss of 8 cents per share in the second quarter of last year.
Adjusted diluted earnings per share for the second quarter of 2025 with 7 cents. Same as the second quarter of last year.
Moving to the balance sheet, we finished the quarter with 162.3 million in cash and cash equivalent.
As of June 30th 2025, we had 297 million of outstanding borrowings on our Term Loan and full of availability under our revolving credit facility.
Earlier this year, our board authorized a $100 million share repurchase program. As of today, we have purchased a total of $25 million in stock, all of which was during the second quarter.
We are reiterating our guidance today as follows. We expect total revenue in the range of 415 to 425 million representing growth of 8 to 10% compared to 2024.
We expect him axon to contribute software revenue of 23 to 25 million.
We expect adjusted EBITDA margins between 30% to 32%.
Similar to our guidance last year we anticipate a higher Evita margin at the lower end of our Revenue guidance and a lower ebita margin at the higher end of our Revenue guidance. This will be driven by discretionary investments in R&D which will be managed carefully. Based on the timing of new product, launches and business performance in the second half.
We expect adjusted EPS in the range of 42 to 46 cents per share.
Fully diluted shares in the range of 162 to 164 million and a tax rate in the range of 25 to 30%.
I will now turn the call back over to our CEO. William Furey for closing remarks.
Thank you. John to summarize our message today. We are pleased with the many exciting developments of satara in the second quarter and we remain focused on executing, our growth and profitability goals in 2025.
We continue to make good progress on the software development front and I am looking forward to sharing further updates following some new product launches in the fall.
Operator, can you please open the line for questions?
Thank you. At this time. We will conduct the question and answer session. As a reminder, to ask a question, you will need to press star 1 1 on your telephone and wait for your name to be announced to withdraw your question. Please. Press star 1 1 again.
Our first question comes from the line of Joe ruin of beard. Your line is now open.
Uh great thanks for taking my question. Uh just a quick clarification. The multi-billion dollar addressable Market opportunity, you sighted around Nas is is that incremental to the low single digit billion Tam. You traditionally have discussed for Bio simulation software.
Yes, we're we're looking that at that as what would be, uh, additional opportunity, Joe, uh, based on trying to bring fence, what we think the long term opportunity is
Up or down.
Okay, that that's great uh and then I thought it was interesting uh so Tara had a webinar during the corridor and during the webinar they asked to respond and just what they're currently using uh around NS and I think 40% cited nothing. So that seems like a good opportunity but 30% cited pbpk modeling.
12% with qsp, I guess I would have expected the qsp responses to be a lot higher. What, what's kind of your interpretation of just how, uh, kind of the thinking, is settling out those Sitara need to do more marketing on their part to educate customers around. Uh, maybe the the best course of action. Just, how are you seeing kind of customer? Uh, decision making change now that we're a few months further in?
Where we would see additional opportunity going forward. So you know that that a qsp is a is a growing area in general and, you know, our combination of our existing practice along with applied biomass makes us. The market leader in that spot. So, uh, I would expect that ratio that you cited to, to grow into the future. Yeah, Joe, I think, um, the other thing to be aware of its, um, still pretty early days on terms of the markets.
Um, thinking about what this announcement means and how it's going to play out as drug programs, move forward.
You know, the reality is qsp and PVP pbpk are.
Often quite closely linked. Um, and so I think
people may answer the question a little bit differently depending on sort of what they're more familiar with when they go in qst is a
Sort of a newer branch of model, informed drug development. And so, you know, the number that you cite. It doesn't really concern us obviously. We're pretty big in, in both of them. Um, but, you know, I think it's, uh, you know, the way I think about it is that it's up to 70% of people that are using, uh,
Using technologies that uh, you know, that we're pretty good at.
Uh, great. Thank you very much.
Thank you.
Our next question comes from the line of Luke sergot of Barclays. Your line is now open.
Hi guys. This is Anna kazinsky on the Luke. Thank you for taking our questions was wondering. If you could give any caller on the demand drivers for software versus Services, bookings.
We would think that the service is booking strength is like a better leading indicator of future spend and adoption. So it would be great to get your sense of this.
Yeah, I think uh it's a good question. Uh, we don't
I think that um might not be quite the right way to look at it. I think the demand drivers are software to some extent. You know, companies need the software as um
Part of the R&D infrastructure. So that continues. But we have also put quite a bit of
um, R&D resources over the last, you know, periods into new products, which is driving some of that uh, demand there, um, Services, um,
You know, it's, uh, it's come back nicely in the quarter, uh, you know, particularly compared with where we were, uh, last year. Um, I think there are several things going on there. 1 of them is been, uh, particularly high demand for qsp services which, um, which is kind of a newer, new new growing areas. I talked before.
um, a second piece has been
the linkage of the services to some of the software that I just talked about. The people are buying. So the, the, you know, we talk about software and services as separate lines. But in fact, they're often quite, uh, closely intertwined when we're actually making sales to customers. And so, they're 1 drives the other
All right, thank you. That is super helpful. Um, 1, quick follow-up. Uh, can you share a little bit more on the Dynamics that you saw across customer peers? Um, the the biggest difference is between Tier 1 Behavior versus tiers 2 and 3. Um, particularly on the software side,
See.
Yeah, sure.
Sure. So um, so we did see Tier 1 software as you saw in the chart with impacted my timing of uh of renewals. But you know as we look uh at the full year basis and in the second half, we have high confidence and good visibility and to be able to achieve those renewals. Um, so that that was the 1 spots that
You know, as you look at tier 3's You know, despite the funding environment then we've had strong performance on both software and services in tier 3. So we've been pleased with that. And we had a particular Bill mentioned. We had a particularly strong quarter on Services, both bios Sim services on the on the Tier 1 side. That is both bios and services and in regg. That was uh, that was helping our overall growth rate their
Awesome. Appreciate all the colors.
Thank you.
Our next question comes from the line of Jeff. Go of Stevens. Your line is now open.
Customers as they might adopt that new platform in the future, you know, more specifically does the um does the delivery model or economics between you guys and customers look any different? And and lastly, there any concern over potentially pushing out demand ahead of an exciting new product launch.
Okay, yep. Uh, thank you, Jeff appreciate the question. Um, so several questions there. Uh, look, we're creating, you know, we, we believe that we have the industry-leading technology around bio simulation. And as I said in the call,
we've made some very, um,
uh, strategic Acquisitions in the AI area. Um,
you know, the opportunity there is to create a bigger platform that unites a number of our
Our software solutions work in different areas of drug development, integrated into one platform, so that drugs can be optimized according to multiple parameters. Basically, our customers can make better decisions about which molecules to bring forward.
Um, we're really excited about this. We think that there's a um
A.
Very significant opportunity for the company and frankly.
For our customers to make much better decisions on which drugs to bring forward. That's that's an opportunity here. Um, and the reason we highlighted it now is not so much to to kind of pre-announce a product. But, you know, we are spending a fair amount of R&D to, uh, to produce this. We've got a plan to, to launch this over the next year. As I said, I'm not particularly worried about your, uh, concern about, uh, customers, kind of waiting it out. Um, most of our customers, you know, are pretty
um,
uh, highly, you know, uh, interested in using our existing products on their current drug development products, it's become in for a lot of people, really part of the standard way that you do, uh, some of the, some of the key technical Parts in, in, in m. So I don't think we'll see, people pause that. Um, this is going to be a new product that's going to be over, you know, over on top of what. Um,
What we sell today? It's got capabilities that are beyond what we what we have today. Um,
you know, like a lot of companies, you know, the Advent of the
Of, uh, of the AI advances that have happened recently have kind of changed the game in terms of what's possible and we're going to implement that in our, so stay tuned. You know, we we haven't fully announced the product
Um, the first part is, be the first part; however, it is in fact being launched in Q4 and is in the hands of customers. But there'll be more to that.
As we go forward over the next year.
Great appreciate that Eric really helpful and maybe to kind of translate some of the the the key themes there to the the financial model you know. Not not just this this new platform but you you've had co-author um released kind of last year and and growing this year, you you have regular releases of of your existing products and and some other new ones as well. You just want to get your um viewpoint on whether a product launches alone, our sufficient to to drive organic growth out of the the the low single digit to Mid single digit Reign range that the company's been in the last few years or if you if you really do need a, a, a better macro environment on top of that, thanks.
Yeah, thanks for the question. Um, we would love a better macroeconomic environment. We are not.
Planning on that and we're not dependent on that. We believe that the company is in a very unique and valuable spot where, um, you know, it's kind of a
combination of, um,
Maturity of technology and understanding by a lot of the industry has and how to use this and acceptance by The Regulators. All of them are coming together in a good way at the same time. And so, you know, as we can, this is a good time for us to, to expand our product Suite because the possibilities of what we can do are are expanding, but we don't need any kind of recovery of the market in order to deliver the, the, uh, results that we're expecting now. So at some point, markets, go up and markets. Go down some for markets will go up and that'll be great, but that's not necessary for our model.
Uh, appreciate that. Thanks again.
Thank you.
Our next question comes from the line of Michael churny of blink. Your line is now open.
A question on the EMA qualification for Sim sip, um, I know this. This just came out. But, um, how are you thinking about that in terms of differentiating your product? You know, any early customer feedback on receiving that? Um, would would be great to hear? Thank you. Yeah, thanks for the question. I think that's been a that's been. Um,
Uh, a real accomplishment, by our teams, uh, our teams seeing both of the EMA and and the sitaro they've been work. We've been working on this for
Better part 2 years right now, to get this qualification, um, this is, uh, a significant the way I would explain this is, uh, the EMA, like other Regulatory Agencies has accepted the use of Sims in drug applications for some time now. However, uh, you know, the EMA are really consists of 27 member nations. And there was no particular, uh,
Qualification of any product there. So for a lot of our customers, it would depend a little bit on, you know what, the, you know, what, what reviewer you got and what questions they asked, and, you know, that added time and and someone's certainty to the overall process. So reviewers, you know, reasonably want to know what's in the models and they want to go qualify it. What this does is that it it basically provides a pre-qualification. So the EMA is effectively saying that, you know, Sims has been
All all of the underset, pendings of sim sip have been explained and examined. And you know, you don't need to do that. Uh, an approver does not need to do that again. Uh, in the middle of a of a drug. Uh,
Application. So no 1 else is uh achieve this it's it's certainly not easy to do the I mean it was a really expensive review. Um,
and uh,
You know, it's not easy to to get there. Uh, but for our customers, this adds 2 things, I think 1 is its, you know, kind of a
sign of, um,
what The Regulators think about the software. So they they've looked hard at it and then and, um,
And accepted it. Uh and the second 1 is just from a practical standpoint it UPS the
um,
the consistency of what you can expect when you go into a review process. Um,
Because you don't have to worry about what questions, you might get about the underpinnings of, of sim sip. That's already kind of taken care of before before we've gotten their. Uh, and it just makes it a whole lot easier to uh, to plan, you know, to to use the software uh, in the review process. And to uh, you know, expect consistent results.
Thank you.
Our next question comes from the line of Kyle Cruz of UBS your line is now open.
Hey, thank you for taking the questions, the software bookings, the client organically, but it sounds like it's related to a timing issue with Tier 1 customers where you have more visibility into 2, H Beyond 2 H, and given kind of a heightened visibility and future orders, could you provide early framing thoughts on 2026 relating to you know, the headwinds with pharma's potential mfn and a potential reduction in Pharma R&D spend offset by the continued regulatory, push for model, informed drug development and if you expect girls to accelerate into 2026 and how much and any early qualitative claiming costs there, thank you.
Hi Kyle. Yeah, I think the right way to think about this is in terms of the Investments that we're making in R&D and the product launches that bill has been referring to and the expectation that we don't, uh, rely on or expect the End Market environment to necessarily improve in the near term. Uh, but we do intend to grow the business in the face of that. And so, you know, we as we look at products that we've rolled out recently, we look at the strength of the existing platforms of callout Sim, as as, uh, as a key highlight on in this quarter, in that sense. Um, and then you combine that with the product launches that we're heading,
Toward uh, inside of this year. Then that sets up uh a nice platform for growth as we look at next year.
Great, thank you for that. And then maybe could you discuss how you aim to get Regulators comparable with incorporating AI into model? Informed drug development.
Um yeah, we'll talk more about that as we launch this. Uh but I think
The.
the um,
just saying Ai and model for drug development, doesn't cover all of the possibilities. So I think a, um, you know, as a regulator, I think you have to be
Blackbox for an AI is making a recommendation.
That you don't understand how they got there. Uh we're well aware of that and that's not what this does. What this type of uh technology does is it allows
Uh, AI to process a lot of the scientific information, we need to create models.
Uh, and it allows us to build models much more quickly with our experts. Um,
But still in a explainable way. So in in in you know in mid you know the name of the game is really explainability, we have to explain what's in the model.
You know, why does the, uh, you know, where do we get it? What are the equations? Where's the data? That backs us up and that's not going to change. Um, and so I think that that that you know, Regulators could feel comfortable about that. But the process of how you get there and the process of how you use, you know, some of the really top experts that we have in satara um can get a lot better. Uh, it basically, we can bring down the cost of creating these models. We can bring down the time of creating them and uh,
You know, we can speed up the overall cycle that's uh that they're used on in the in the drug development process.
Great. Thank you so much very helpful.
Thank you.
Our next question comes from the line of Brendan Smith of TD Cohen. Your line is now open.
Great. Thanks for taking the questions guys. Uh, and thanks for all the color. I I wanted to ask just another 1 actually about some of the new customer inbounds uh in in the wake of fda's pushing animal testing. I think you called out of a 50 percentile uh, for non-animal testing Arena. So I guess can you just maybe remind us how we should think about kind of the Cadence over the next couple of quarters of really, how? And when some of the new bookings are or even I guess, new preliminary inquiries could could translate into any upside. Um, I mean, I, I totally understand there's, there's always some variability in customer timing and all that but just trying to understand some of your internal assumptions around, you know, a brand new customer comes to you specifically because of FDA, you know what you expect.
Kind of average time from first Outreach to revenue recognition for you all. Looks like maybe what some of those considerations have been uh this quarter.
Yeah. Well probably the first thing that highlight Brandon would be um, you know, the qsp business and The Sims business. We've said previously would be the areas that would be uh, currently initial beneficiaries here. Uh, that being said, we, we do think it's a long-term conversion, uh, as we discussed earlier in the call, but we have seen, uh,
We've seen strength in qfd incentive as we, as we mentioned earlier in the quarter, and as we look at the remainder of the year, there's, you know, there's certainly potential upside in in those 2 areas, um, which is both services and qsp services, and since it software. So, uh, the customer conversations, um, have been good and I think that we're, you know, we're increasing the dialogue, um, while at the same time, those businesses are, you know, outperforming our expectations on the year.
Okay, got it. Thanks guys.
Thank you.
Our next question comes from, Stephen dechert of KeyBank. Your line is now open.
Hey guys, just want to dig into the Tier 1. Slowing of software, renewals anything specific to point to you there.
No. I the the way to think about it is that, you know,
bookings are
bumpy on a quart.
Historically Revenue was strong or organic Revenue at 9% TTM uh, organic bookings were 11%. So that's indicative of what what we've been booking and we have good visibility into the second half renewals during the year. So uh, that gives us a lot of confidence as we approach the remainder of 2025.
Okay. Thanks and then given the strength you're seeing in qsp. What's the profitability of that product relative to your other offerings? Thanks.
Okay, thank you.
Thank you.
As a reminder, to ask a question, you will need to press star 1 1 on your telephone.
Our next question comes from the line of Max mock of William Blair. Your line is now open.
Hey, good afternoon, guys, thanks for taking our questions. Maybe just following up on an earlier, question around qsp, and you flagged the 50% of new engagements, tied to mad this kind of a proxy for
The uptick in demand you think you've seen since uh the FDA guidance is released but just wondering if you can give some more context around, you know what the breakdown of therapeutic modality looked like for qsp, pre FDA guidance and then any contacts you have around what portion of those engagements, uh, that you flagged in the quarter wouldn't have been 1 in your opinion without that FDA guidance.
um,
Yeah. Thanks, Max, for the question. Um,
So Q is so, uh, qsp.
Has.
Been working heavily on maps for some time.
Uh,
the FDA made an announcement, which
I think is a result of the fact that there is part. I'm guessing as a result of the fact that there is so much modeling going on in that and you can get uh, you can get some pretty good.
Um, answers out of that.
Uh I would I'm not going to give you the specific numbers but there's been some of an uptick since the FDA made their announcement. I think however you know
The it wasn't like the FDA made an announcement in the next day, all of a sudden.
you know everybody switched to using qsp there's a you know there's been a process
Since the announcement kind of started with 1 of the webinars that we you know, very well attended webinars, that we gave right after the FDA announcement um where companies have been exploring, what's the possibility and what what's the meaning of what the FDA is talking about? Um, and during that process, a lot of them learned about the
you know, the benefits of qsp and and we picked up from there, so it's been good for business so far, is it, uh, you know,
Is it like at the maximum rate now, it's going to take some time for the market to, to Really build up and gain confidence about, you know, exactly how does the FDA want this to play forward, but it's defin driven, a lot of interest in that type of modeling.
And um, you know, it's driven revenues to the company. So I'll just leave it there.
That's helpful, understood. Thank you. Um,
Maybe turning to margins. You know, the midpoint of the guide implies about 30% in the second half its going to well below. You did 32 in the first half and I know you talked about hiring being a driver there, but can you just walk through any of the other kind of factors that are leading to that step down in 2 H in the second half of the year and then the Cadence between the third quarter and fourth quarter? And then John I think more importantly is 4K going to be a good jumping off point for thinking about margins next year, or are you going to moderate Investments to make sure that you're protecting margins in 2026?
Yeah. Hi Max. So um, the so first half was impacted by some, uh, slower hiring in q1. So the the best way to, um,
Uh model for for the remainder of the year is the Q2 is a good jumping off point. So the March our 30.5% margin in Q2 is a good way to think that you know as we've ramped as we continue to ramp the Investments coming out of Q2 and into Q3 and Q4 then uh that's you. You know, the Q2 margin is the good proxy.
And Q wanted less. So so I took this more on the quarter than the first half as the way to think about how to um model the the full year from a margin perspective because of those Investments coming in.
um, and then, as far as the jumping off point for the margin uh next year, sort of
Aligned with what I was just saying, you know, the Investments that we're making, uh, are you know that hiring is going to take place during uh some of it was in to Q. Uh, they'll be more of it in Q3 and into Q4. So I would say that uh Q4 would be a decent proxy for where we go ahead into the next year.
Got it. Thanks again for taking our questions.
Thank you.
Our next question comes from the line of Gabrielle Winer of Jeffrey's your line is now open.
Dave, windley here. The is it me? I think it's probably me. Um, if you can hear me. Uh, so,
All right, thanks for taking my question. Um, I wanted to ask around a kind of adoption curve. So sir tar has been um, in this modeling business for, you know, couple decades, probably seen several adoption curves. And so my question is, what are the telltale signs?
Of clients that are on the cusp of, you know, say climbing the steeper.
Uh, looking at the adoption curve, is it hiring more people in their quantitative sciences divisions? Is it running pilot programs?
Um what might that look like and and I'm I'm asking as a you know as something to look for as relates to the NS and how we might try to observe um Pharma companies stepping into adoption.
Uh, of nams, thanks.
Yeah, thank you David. Um, it's a complicated, uh, question because of the
The many different players in this market. And frankly, the lots of
Just a technical aspect of where bias simulation is used. But if I want to generalize.
You know, the uh, we often start with services, so a company. I don't it's not exactly a pilot program.
but the first 1 through often,
Uh is a project that gets conducted by certara and then as companies get uh excited and and feel confident in what we're doing, uh they become uh, they become software, you know, customers as we go forward. So if we look at that on NAS it, you know, I don't I guess say um,
Nas is kind of an interesting thing because it's only, you know, this whole
Announcement from the FDA has only been around a few months, which is really no time in the way Pharma operates.
Uh,
Yet, there has been a tremendous amount of Interest.
We've been hired to do.
everything from additional qsp projects to
You know, strategy projects around, what does this mean for my drug? And how do I change the way I think about, um, of bringing it forward?
Um, and that's happened very, very quickly. So, you know, we're we're sort of trying to project off just a few months as to how this is going to play out over a multi-year process going forward here. Um, but you know, I think, um, in this case, what we see is number 1,
You know companies are very interested in in Nas, right? Uh a number of them.
kind of combine this with a
uh, you know, a a test of additional modeling or bio simulation uh, in their projects. Um, so it's all good in terms of its drying driving business to us, but it's it's a little bit convoluted about um, you know, maybe they're they're and often and often times trying to do multiple things when they start working with us.
yeah, maybe as a follow-up to that is
our and and trying to understand
um how the client might use or might try to arrive at the answers that they're trying to achieve without using animal models and and, and so much as
Sensitive is an area that you're pointing to is as being invoked by this. Um, qsb is a little newer but but like let's focus on Sims is
Is the client.
Using Sims it in a different way to produce different answers than the clients. Have typically used Sims to do.
Or are they?
You know, kind of running similar, you know, maybe more intensive but similar types of analyses.
We are modeling as they've done with SimSip in the past, but just our...
They trusting those answers more and moving on without, you know, say, verifying in animals.
So, the way I could explain it is this for some time.
many of our customers have been doing modeling in monoclonal, antibodies in parallel to their animal testing,
And they're the modeling has produced.
Results. That
Hosting.
Its 1 thing to try that on a primate but you can get a much better answer.
uh, if you use modeling, and if you get a better answer, you're more likely to
To uh, make better use of your Phase 1 trials where you're trying to figure out the, the effective dosing range. So that's why they're doing that that data. However, now everybody's looking at it and saying, wow, you know,
We can use some of this data and we can, you know, if the FDA allows this, we can reduce the number of animals as we go forward. So that's good. But those are our customers that are already working on it. They're taking some of the modeling they were doing with other reasons and they're and they're sort of like getting some additional benefit and then other companies that were maybe on the fence about doing that are saying well you know we could you know we ought to start taking a look at qsp as well. So that's why we say that this has been
This has been good for business so far. Um,
there's still some quite, I mean, I I don't think anybody's actually gotten to the point of taking uh, a drug application to the FDA with
You know reduced use of animals so far as there's only been like I said it's only been a few months, you know? Hopefully as that happens then we'll see some kind of a
Snowballing effect as as that dries, even more interest.
Very helpful. Thank you.
Thank you.
I am showing no further questions at this time. Thank you for your participation. In today's conference, this does conclude the program. You may now disconnect